Maxele Advisors LLC Buys Shares of 10,686 Abbott Laboratories $ABT

Maxele Advisors LLC acquired a new stake in Abbott Laboratories (NYSE:ABT) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,686 shares of the healthcare product maker’s stock, valued at approximately $970,000. Abbott Laboratories makes up 0.7% of Maxele Advisors LLC’s portfolio, making the stock its 24th biggest position.

Other institutional investors have also recently added to or reduced their stakes in the company. Nia Impact Advisors LLC boosted its position in Abbott Laboratories by 2.2% during the second quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after acquiring an additional 79 shares during the last quarter. Riggs Asset Managment Co. Inc. raised its holdings in Abbott Laboratories by 9.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock valued at $140,000 after acquiring an additional 88 shares during the last quarter. Eley Financial Management Inc raised its holdings in Abbott Laboratories by 0.9% in the 4th quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock valued at $1,355,000 after acquiring an additional 92 shares during the last quarter. Copley Financial Group Inc. lifted its stake in shares of Abbott Laboratories by 2.1% during the 4th quarter. Copley Financial Group Inc. now owns 4,435 shares of the healthcare product maker’s stock worth $556,000 after purchasing an additional 93 shares during the period. Finally, Kelleher Financial Advisors boosted its holdings in shares of Abbott Laboratories by 2.9% during the third quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker’s stock worth $442,000 after purchasing an additional 93 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the subject of several recent analyst reports. TD Cowen lifted their price target on Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, August 25th. Robert W. Baird began coverage on shares of Abbott Laboratories in a report on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target on the stock. Royal Bank Of Canada restated an “outperform” rating and set a $130.00 price objective on shares of Abbott Laboratories in a report on Friday, July 17th. BTIG Research upped their price target on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research note on Friday, July 17th. Finally, JPMorgan Chase & Co. lifted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, July 17th. Three research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $119.50.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott shares outperformed the broader market in the latest session, suggesting continued investor support for the diversified healthcare-products company. The move adds to its gains above both its 50-day and 200-day moving averages. Abbott Exceeds Market Returns: Some Facts to Consider
• Neutral Sentiment: A separate market comparison reported that Abbott underperformed its competitors during Tuesday’s trading session. The article did not identify a company-specific operational problem, making the relative weakness more relevant to short-term sentiment than to Abbott’s long-term fundamentals. Abbott Laboratories Stock Underperforms Tuesday
• Neutral Sentiment: Vice President John McCoy Jr. sold 27 shares for approximately $2,958. The transaction reduced his direct holdings by only 0.11%, leaving him with 24,549 shares, so it is too small to represent a meaningful change in insider conviction. SEC Insider Transaction Filing
• Neutral Sentiment: An investor-focused healthcare article mentioned Abbott primarily as the former parent of AbbVie, rather than discussing new developments at ABT. It therefore provides little direct information about Abbott’s near-term earnings or valuation. Abbott Laboratories Company Information

Abbott Laboratories Price Performance

Shares of ABT stock opened at $108.81 on Friday. The firm has a fifty day moving average of $104.14 and a two-hundred day moving average of $100.06. The firm has a market cap of $188.28 billion, a P/E ratio of 35.21, a P/E/G ratio of 2.05 and a beta of 0.59. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The business had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.